Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 4/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2656747 | 0.75 | CCR4 (0.33) | — | |
| SCHEMBL2656822 | 0.72 | AR (0.40) | KDM4EALDH1A1HPGDHTTL3MBTL1 | |
| SCHEMBL2657423 | 0.72 | TLR8 (0.32) | KDM4E | |
| SCHEMBL22045089 | 0.71 | HPGDS (0.45) | HPGDSKDM4EALDH1A1HTTL3MBTL1 | |
| SCHEMBL31314246 | 0.69 | GRM5 (0.37) | HPGDSKDM4EALDH1A1HPGDHTT | |
| SCHEMBL14120504 | 0.69 | APLNR (0.37) | KDM4EALDH1A1HPGDGRM5 | |
| SCHEMBL2429966 | 0.69 | KDM4E (0.46) | KDM4EALDH1A1HPGDHTTL3MBTL1 | |
| SCHEMBL29434547 | 0.69 | KDM4E (0.46) | KDM4EALDH1A1HPGDHTTL3MBTL1 | |
| SCHEMBL7971066 | 0.69 | RAF1 (0.33) | KDM4EALDH1A1HPGDHTTL3MBTL1 | |
| SCHEMBL2470931 | 0.69 | HPGDS (0.46) | HPGDSKDM4EALDH1A1HTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | HPGDS 4632/4885KDM4E 2357/4885ALDH1A1 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.